Introduction {#sec1}
============

Serum total 25-hydroxyvitamin D~3~ \[25(OH)D~3~\] is the major form of vitamin D in circulation, and this measure is widely used as a biomarker of vitamin D status ([@bib1]). Approximately two-thirds of the US population has vitamin D insufficiency, as defined by serum 25(OH)D~3~ levels ≤75 nmol/L (equivalent to \<30 ng/mL) ([@bib2]). Low serum total 25(OH)D~3~ levels have been associated with cognitive impairment ([@bib3], [@bib4]) and Alzheimer\'s disease ([@bib5], [@bib6]) in both cross-sectional and longitudinal analyses. However, the total 25(OH)D~3~ level in cerebrospinal fluid was not associated with neurologic diseases in the Korean population ([@bib7]). For this reason, it is unclear whether relying on serum total 25(OH)D~3~ levels is a valid or optimal indicator of vitamin D status and function in the brain. It has been demonstrated in a rat model that serum and brain 25(OH)D~3~ levels are correlated ([@bib8]). However, it is not known which forms of vitamin D are in the human brain. This gap in knowledge limits the ability to interpret the studies that correlate low circulating forms of 25(OH)D~3~ and onset of cognitive impairment.

Unlike the advances in measurement of serum 25(OH)D~3~ ([@bib9]), the pace of developing and standardizing assays for measurement of vitamin D and its metabolites in tissues has lagged behind. Most existing detection methods for vitamin D and its metabolites in plasma or tissues have utilized LC-MS/MS, with ionization methods ranging from electrospray ionization (ESI) ([@bib8]) to atmospheric pressure photoionization ([@bib12], [@bib13]) and atmospheric pressure chemical ionization ([@bib14]). There is also variability in solvent extraction methods, including acetonitrile ([@bib8]), acetone ([@bib12], [@bib14]), immunoaffinity extraction ([@bib15]), and dichloromethane: methanol mixture (DCM: MeOH) ([@bib13], [@bib16]). Derivatization methods have been developed to augment the ionization efficiency of vitamin D~3~ and its metabolites in order to enhance detection ([@bib8], [@bib11], [@bib14]). Despite these developments, most available assays have only been optimized for a single analyte. In contrast, simultaneous quantitation of vitamin D~3~, 25(OH)D~3~, and 1,25-dihydroxyvitamin D~3~ \[1,25(OH)~2~D~3~\] in a single extraction from human brain with minimal tissue required has proven difficult.

The objective of this study was to develop and validate a method to quantify vitamin D and its metabolites in human brain. The availability of this assay will enable research into the potential relationship between plasma vitamin D status and cognitive function, including potential linkages to Alzheimer\'s disease.

Methods {#sec2}
=======

Chemicals, regents, and standards {#sec2-1}
---------------------------------

Solvents used for sample extraction and chromatography were ultra-HPLC grade. Vitamin D~3~ (VD~3~) and vitamin D~3~-\[23,24,25,26,27--^13^C5\] \[^13^C-VD~3~ as internal standard (IS)\], 25-hydroxyvitamin D~3~ and 25-hydroxyvitamin D~3~-\[23,24,25,26,27--^13^C5\] \[^13^C-25(OH)D~3~ as IS\], and 1,25-dihydroxyvitamin D~3~ and 1,25-dihydroxyvitamin D~3~-\[d6\] \[d6--1,25(OH)~2~D~3~ as IS\] were purchased from IsoScience. The calibration standards were prepared at a concentration of 10 ng/mL in methanol. All the stock solutions and working standards were stored at −80°C. 4-Phenyl-1,2,4-triazoline-3,5-dione (PTAD; 0.25 mg/mL) in acetonitrile was used for derivatization.

Samples and clinical application {#sec2-2}
--------------------------------

The validation experiments were performed using commercially obtained porcine brain (Pel-Freez Biologicals). The porcine brain was manually homogenized using mortar and pestle under liquid nitrogen, aliquoted, and stored at −80°C.

This method was used to characterize vitamin D and its metabolites in a whole human brain obtained from a 54-y-old woman donor through the National Development and Research Institutes. The fresh brain was collected and shipped to the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University within 24 h after death. The brain was dissected into 8 different anatomical sections (cerebellum, medulla, pons, hypothalamus, prefrontal cortex, corpus callosum, middle frontal cortex, and middle temporal cortex) by a trained neuroscientist (TZ) and stored at −80°C until analysis. A single measure from each region was obtained. To verify that all 3 metabolites could be measured in human brain, this method was also applied to the prefrontal cortex of 1 postmortem brain sample (91-y-old man) obtained from a participant in the Rush Memory and Aging Project (MAP) ([@bib17]) for measuring vitamin D and its metabolites.

This study was approved by the Institutional Review Board at Tufts University. The parent study (MAP) was approved by the Institutional Review Board of Rush University Medical Center.

Preparation of brain samples {#sec2-3}
----------------------------

Brain tissues were weighted to 0.1 g and 0.5 mL of DCM:MeOH (1:1, vol:vol) was added prior to homogenization using a benchtop PowerGen 125 Fisher Scientific homogenizer. The extraction procedure used was a modification of steps used to extract vitamin D~3~ from mouse brain ([@bib12]). Twenty microliters of IS solution \[containing 250 ng/mL ^13^C-25(OH)D~3~, 250 ng/mL d6--1,25(OH)~2~D~3~, and 500 ng/mL ^13^C-VD~3~ in methanol) and 0.5 mL DCM:MeOH (1:1, vol:vol) were added to the homogenized samples. After vortexing for 5 min, the samples were centrifuged at 4°C for 5 min at 13,200 rpm. The supernatant was then transferred to a glass tube. 0.5 mL methylene chloride:methanol mixture was added to resuspend the pellet, and the previous step was repeated. The supernatants were pooled together and subsequently dried under nitrogen gas (Organomation Multivap Nitrogen Evaporator) with heat (60°C). For derivatization, 200 μL of PTAD solution (0.25 mg/mL in acetonitrile) was added to the residue, followed by 10 s of vortex, and the samples were subsequently stored in a dark place (room temperature) for 1 h. The calibration standards and samples were dried under nitrogen gas again and then reconstituted in 100 µL of mobile phase (water:methanol: 1:1 vol: vol) with 20 mM methylamine and 0.1% formic acid, then centrifuged (at 13,200 rpm for 5 min), and the supernatants were pipetted into a vial with a glass insert before analysis.

Quadrupole ion trap instrumentation and conditions {#sec2-4}
--------------------------------------------------

The LC-MS/MS system included an Agilent series 1290 LC instrument (Agilent Technologies) coupled to a tandem quadrupole Sciex 5500 quadrupole ion trap (QTRAP) MS system. The chromatographic separation column was a C~18~ analytical column (Waters Cortecs; 2.7 μm, 50 mm × 2.0 mm). The injection volume was 20 μL. Mobile phase A was 4 mM methylamine in water with 0.1% formic acid, and mobile phase B was 4 mM methylamine in methanol with 0.1% formic acid. The gradient program operated with a flow of 0.1 mL/min: 0--2 min, 50% B; 2--4 min, gradient from 50% B to 100% B; 4--25 min, 100% B.

MSD (5500 QTRAP MS system) settings were as follows: ion source, positive ESI; temperature, 450°C; ion source gas 1: 50 psi; gas 2: 50 psi; curtain gas: 20 psi; collision gas: medium; ion spray voltage, 5500 V; declustering potential: 55 V; entrance potential: 4 V; collision energy: 20 V; collision cell exit potential: 10 V. The multiple reaction monitoring (MRM) transitions used are shown in [**Table 1**](#tbl1){ref-type="table"}. Data were collected using Analyst software.

###### 

MRM transitions used[^1^](#tb1fn1){ref-type="table-fn"}

  Vitamin D                   MW (mol)   MRM transition (*m/z*)
  --------------------------- ---------- ------------------------
  Cholecalciferol                        
   VD~3~                      384.64     591.2/298.1
   ^13^C-VD~3~ (IS)           389.60     596.2/298.1
  Calcifediol                            
   25(OH)D~3~                 400.65     607.2/298.1
   ^13^C-25(OH)~2~D~3~ (IS)   405.59     612.2/298.1
  Calcitriol                             
   1,25(OH)~2~D~3~            416.64     623.4/314.1
   d6--1,25(OH)~2~D~3~ (IS)   422.67     629.4/314.1

IS, internal standard; MRM, multiple reaction monitoring; MW, molecular weight; VD~3~, vitamin D~3~; 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D~3~.

Validation experiments {#sec2-5}
----------------------

Linearity was determined for vitamin D and its metabolites following serial dilution of a calibration standard to concentrations ranging from 5000 to 10 pg/mL. Regression coefficients were determined for each compound separately using linear regression.

The limit of detection (LOD) for vitamin D and its metabolites was determined by spiking porcine brain with serially diluted vitamin D standards ([**Table 2**](#tbl2){ref-type="table"}). The LOD was defined as the lowest analyte concentration statistically different from 0 with a relative SD (RSD) of ≤20% over triplicate measurements.

###### 

Detection limits and intra-assay, inter-assay, and recovery variability of QTRAP assay for vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~[^1^](#tb2fn1){ref-type="table-fn"}

  Validation                            VD~3~   25(OH)D~3~   1,25(OH)~2~D~3~
  ------------------------------------- ------- ------------ -----------------
  LOD, pg/g                             25      50           25
  Recovery (*n* = 6), %                 99.5    99.4         104.3
  Interday precision RSD (*n* = 6), %   9.0     6.9          10.7
  Intraday precision RSD (*n* = 6), %   5       4.5          4.5

LOD, limit of detection; QTRAP, quadrupole ion trap; RSD, relative SD; VD~3~, vitamin D~3~; 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D~3~.

Both intra-assay and inter-assay variability were determined for vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~ in spiked porcine brain (*n* = 12). The precision was determined based on the coefficient of variation of vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~ concentration in the samples spiked before extraction and purification. The inter-assay variability was determined by repeating the same procedure on 4 consecutive days.

Quantification {#sec2-6}
--------------

The response factor (RF) of the vitamin D~3~ was calculated by dividing the vitamin D~3~ peak area by the IS (^13^C-VD~3~) peak area, followed by multiplying by the amount of IS. Similarly, the RF of the vitamin D~3~ in samples was calculated by dividing the vitamin D~3~ peak area by the IS peak area, followed by multiplying by the amount of IS added. The quantification was obtained by dividing the sample RF by the standard RF and then multiplying by the total amount of vitamin D~3~ standard and the dilution factor. We applied the same quantification method for 25(OH)D~3~ and 1,25(OH)~2~D~3~ as well.

Statistical analysis {#sec2-7}
--------------------

Linearity, slope, and regression coefficients were determined by linear regression. Student\'s paired *t* test was used for determination of LOD. All statistical analyses were performed using Microsoft Excel 2010. Results were considered statistically significant if the observed significance value was *P* \< 0.05.

Results and Discussion {#sec3}
======================

Optimization of extraction conditions {#sec3-1}
-------------------------------------

Lipids account for ∼60% of the brain\'s dry weight, and the composition of these lipids is very complex ([@bib15]), so extraction of vitamin D~3~ and its metabolites from brain is challenging. Liquid--liquid extraction, solid-phase extraction, and lipase have been utilized for extraction of vitamin D or its metabolites in different matrices ([@bib8], [@bib12], [@bib18]). Acetonitrile, DCM:MeOH (1:1, vol:vol), hexane, and acetone were compared to determine the best extraction solution. The DCM:MeOH (1:1, vol:vol) extraction method obtained the highest recovery for all 3 compounds. Furthermore, different concentrations of PTAD (0.1, 0.25, 0.5, 1.0, and 2.0 mg/mL) were also tested. PTAD at a concentration of 0.25 mg/mL was chosen for the maximum yield. This method required only 1 h of PTAD derivatization, which significantly decreased the sample preparation time, in contrast to an overnight step reported in prior studies ([@bib8]).

The method showed good linearity of vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~ over the physiological range (*R*^2 ^= 0.9995, 0.9968, and 0.9970, respectively) ([**Figure 1**](#fig1){ref-type="fig"}).

![Linearity of vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~ by UHPLC-QTRAP. QTRAP, quadrupole ion trap; UHPLC, ultra-HPLC; VD3, vitamin D~3~; 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D~3~.](nzz074fig1){#fig1}

The LOD of vitamin D~3~ was 25 pg/g ([Table 2](#tbl2){ref-type="table"}). Compared with the few published methods measuring vitamin D~3~ in tissues ([@bib19]), our method has a significant improvement of the LOD for vitamin D~3~. Jakobsen et al. ([@bib21]) reported that the LOD of vitamin D~3~ was 30 ng/100 g for 50 g of meat sample by LC. Notably, a very small amount of sample was used in our experiments, whereas a high sensitivity was achieved. Usually, samples of up to 50 g are required to extract vitamin D~3~ in food or meat ([@bib21], [@bib22]). Because our method only required 0.1 g samples, it is well suited for analysis of vitamin D~3~ in small quantities of animal or human tissue. Blum et al. ([@bib23]) reported a method to measure vitamin D~3~ in fat tissue using small quantities (0.2--0.25 g) of sample. The LOD of 25(OH)D~3~ and that of 1,25(OH)~2~D~3~ were 50 and 25 pg/g, respectively. Our method has much higher sensitivity for 25(OH)D~3~ in tissue samples compared with other methods ([@bib8], [@bib18]). There was only 1 method published for measuring 1,25(OH)~2~D~3~ in mouse brain ([@bib12]). However, the limit of quantitation was 1000 pg/g in mouse brain, which is 20 times lower sensitivity than that of the current method.

Precision {#sec3-2}
---------

The validation data are shown in [Table 2](#tbl2){ref-type="table"}. Precision was investigated using homogenized porcine brains. Intraday precision of vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~ was characterized by an RSD of 5.0%, 4.5%, and 4.5%, respectively; interday precision was characterized by an RSD of 9.0%, 6.9%, and 10.7%, respectively.

Application to human brain {#sec3-3}
--------------------------

The method was successfully applied to the determination of vitamin D~3~ and its metabolites in the human brain ([**Table 3**](#tbl3){ref-type="table"}). No vitamin D~3~ was detected in any examined area of this single human brain. All analyzed human brain regions contained 25(OH)D~3~, with corpus callosum containing 334 pg/g compared with 158 pg/g in cerebellum. 1,25(OH)~2~D~3~ was detected only in prefrontal and middle frontal cortex, and at these sites, it was present at low levels of 30 and 35 pg/g, respectively. [**Figure 2**](#fig2){ref-type="fig"} shows the representative MRM chromatograms for 1,25(OH)~2~D~3~--PTAD, d6--1,25(OH)~2~D~3~--PTAD, 25(OH)D~3~--PTAD, ^13^C-25(OH)D~3~--PTAD, vitamin D~3~--PTAD, and ^13^C-vitamin D~3~--PTAD (F) of prefrontal cortex of the 1 human brain obtained from the National Development and Research Institutes. 25(OH)D~3~--PTAD showed 2 peaks, which are 2 epimers. Recent studies using derivatization with a Cookson-type regent showed *6S* and *6R* epimers because the derivatization regents reacted with *s-cis-diene* moiety from both the α and β sides ([@bib8], [@bib13]). In this case, both of the peaks were integrated for quantification. This is the first report of low 1,25(OH)~2~D~3~ concentrations in human brain. The previous study did not report 1,25(OH)~2~D~3~ concentrations in mouse brain because the method was unable to detect it. This supports the need for an assay that can measure vitamin D metabolites with much lower limits of quantitation.

###### 

Vitamin D~3~ and its metabolite concentrations in 8 sections of 1 human brain as determined by QTRAP[^1^](#tb3fn1){ref-type="table-fn"}

  Brian region             VD~3~ (pg/g)   25(OH)D~3~ (pg/g)   1,25(OH)~2~D~3~ (pg/g)
  ------------------------ -------------- ------------------- ------------------------
  Corpus callosum          ND             334                 ND
  Hypothalamus             ND             332                 ND
  Middle temporal cortex   ND             275                 ND
  Medulla                  ND             265                 ND
  Pons                     ND             250                 ND
  Middle frontal cortex    ND             238                 35
  Prefrontal cortex        ND             233                 30
  Cerebellum               ND             158                 ND

LOD: VD~3~, 25 pg/g; 25(OH)D~3~, 50 pg/g; 1,25(OH)~2~D~3~, 25 pg/g. LOD, limit of detection; ND, nondetectable; QTRAP, quadrupole ion trap; 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D~3~.

![The representative MRM chromatograms for 1,25(OH)~2~D~3~--PTAD (A), d6--1,25(OH)~2~D~3~--PTAD (B), 25(OH)D~3~--PTAD (C), ^13^C-25(OH)D~3~--PTAD (D), vitamin D~3~--PTAD (E), and ^13^C-vitamin D~3~--PTAD (F) of prefrontal cortex of the 1 human brain obtained from the National Development and Research Institutes. MRM, multiple reaction monitoring; PTAD, 4-phenyl-1,2,4-triazoline-3,5-dione; VD~3~, vitamin D~3~; 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D~3~.](nzz074fig2){#fig2}

This method was also applied to the prefrontal cortex of a postmortem brain sample obtained from a participant in the Rush Memory and Aging Project ([@bib17]). The representative MRM chromatograms of vitamin D and its metabolites are shown in [**Figure 3**](#fig3){ref-type="fig"}. Vitamin D~3~, 25(OH)D~3~, and 1,25(OH)~2~D~3~ were all detected in prefrontal cortex of this human brain. This demonstrated there is significant variability in the concentrations of vitamin D metabolites in human brain samples.

![The representative MRM chromatograms for 1,25(OH)~2~D~3~--PTAD (A), d6--1,25(OH)~2~D~3~--PTAD (B), 25(OH)D~3~--PTAD (C), ^13^C-25(OH)D~3~--PTAD (D), vitamin D~3~--PTAD (E), and ^13^C-vitamin D~3~--PTAD (F) of prefrontal cortex of a postmortem brain sample obtained from a participant (91-y--old man) in the Rush Memory and Aging Project. MRM, multiple reaction monitoring; PTAD, 4-phenyl-1,2,4-triazoline-3,5-dione; VD~3~, vitamin D~3~; 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25-dihydroxyvitamin D~3~.](nzz074fig3){#fig3}

In conclusion, to the best of our knowledge, this study is the first report of the measurement of concentrations of vitamin D metabolites in human brain. This validated method can be applied to postmortem studies to obtain accurate information about the presence and role of vitamin D and metabolites in human brain and neurodegenerative diseases.
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